N4 Pharma PLC Attendance at the Company's annual general meeting (9238J)
17 Abril 2020 - 01:00AM
UK Regulatory
TIDMN4P
RNS Number : 9238J
N4 Pharma PLC
17 April 2020
17 April 2020
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Attendance at the Company's annual general meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, provides an update on the Company's annual general
meeting ("AGM"), to be held at 10:00 a.m. on 23 April 2020.
Further to the Company's announcement on 25 March 2020,
Shareholders are reminded that that only the formal business set
out in the notice of meeting will be considered at the AGM and are
discouraged from attending the AGM in person given the current
Government advice. Shareholders wishing to vote on any of the
matters of business are instead urged to do so via completion of a
proxy form which can be completed and submitted to the Company.
Details of how to appoint a proxy are set out in the Company's
Notice of AGM posted to Shareholders on 25 March 2020 and available
on the Company's website, www.n4pharma.com.
As an alternative to attending the AGM, the Company is offering
Shareholders the option of attending a presentation by Nigel
Theobald, CEO, via videoconference at 2:30 p.m. on 23 April 2020.
Shareholders wishing to join should contact Nigel Theobald at
nigel@n4pharma.co.uk. No new information will be provided during
the presentation.
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Scott PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSFDFDMESSESL
(END) Dow Jones Newswires
April 17, 2020 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024